LaNova Medicines Announces First Patient Dosed in Phase I Clinical Trial of LM-350 in Australia

Shanghai, September 29, 2025 - LaNova Medicines Ltd. announced that the first patient has been successfully enrolled in the Phase I clinical trial of LM-350, an innovative antibody-drug conjugate (ADC) targeting CDH17 in Australia. This milestone marks the official entry of this innovative therapy into clinical development.

LM-350 was developed using LaNova's next-generation ADC platform, LM-ADC™. It is a highly selective ADC that targets cadherin-17 (CDH17) with strong internalization capacity. The molecule features a wild-type IgG1 backbone and retains antibody-dependent cell-mediated cytotoxicity (ADCC) activity. In preclinical studies, LM-350 demonstrated potent anti-tumor efficacy across multiple xenograft models, with particularly strong activity in colorectal cancer cells resistant to MMAE or irinotecan.

CDH17 plays a key role in tumor invasion and metastasis and is highly expressed in approximately 99% of colorectal cancers, 86% of gastric adenocarcinomas, 79% of esophageal adenocarcinomas, and 50% of pancreatic ductal adenocarcinomas.Gastrointestinal (GI) cancers—including colorectal, gastric, pancreatic, and esophageal cancers—are among the most prevalent and deadly cancer types worldwide. In 2022, global incidence exceeded 4 million cases, underscoring the significant unmet medical need in this area.

This study is an open-label Phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of LM-350 in patients with advanced solid tumors through dose-escalation and dose-expansion cohorts. LaNova will continue to advance the clinical development of this program at pace, with the goal of bringing new treatment options to patients as soon as possible.